A practical reference on cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-05 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
=== December === 1 December – Ireland's first space satellite, EIRSAT-1, was launched from Vandenberg Space Force Base in the United States, propelled by a Falcon 9 rocket. 6 December – A no confidence motion in Minister for Justice Helen McEntee was tabled in the Dáil by Sinn Féin and countered with a government motion expressing confidence in the minister. The government's confidence motion won, with 83 TDs voting that they had confidence in the minister and 63 TDs voting that they did not. 8 December – The funeral of singer Shane MacGowan took place at St Mary's of the Rosary Catholic Church in Nenagh, County Tipperary. 10 December – Property and vehicles were damaged after a tornado struck Leitrim Village in County Leitrim. 14 December – Twelve people, including eight Transition Year students, were injured in a serious crash between a school bus and a truck in Kilkenny. 16 December – Gymnast Rhys McClenaghan was voted 2023 RTÉ Sports Person of the Year. 17 December – Gardaí began investigating a "criminal damage incident" after a fire broke out at a disused hotel in Rosscahill, Oughterard that was due to accommodate asylum seekers. 20 December – Tánaiste Micheál Martin announced government plans to "initiate an inter-State case against the United Kingdom under the European Convention on Human Rights" over provisions in the Northern Ireland Troubles (Legacy and Reconciliation) Act 2023 which offers immunity from prosecution for certain Troubles-era related offences.
=== Natural occurrence === Hawthorn flowers have a heavy, complicated scent, the distinctive part of which is triethylamine, which is also one of the first chemicals produced by a dead human body when it begins to decay. Due to the scent, it is considered unlucky in British culture to bring hawthorn into a house. Gangrene and semen are also said to possess a similar odour.
However, the situation might be more complex, since modern computational studies have established that traditional examples of proximity effects cannot be related directly to enzyme entropic effects. Also, the original entropic proposal has been found to largely overestimate the contribution of orientation entropy to catalysis.
Sources: en.wikipedia.org
=== In waste disposal === In 2015, it was discovered that 100 mealworms can degrade polystyrene into usable organic matter at a rate of about 34–39 milligrams per day. No difference was found between mealworms fed only Styrofoam and the mealworms fed conventional foods, during the one-month duration of the experiment. Microorganisms inside the mealworm's gut are responsible for degrading the polystyrene, proven by reducing the property of degradation when mealworms were given gentamicin. Isolated colonies of the mealworm's gut microbes, however, have proven less efficient at degradation than the bacteria within the gut.
=== Infantile-Onset (IOPD) === The infantile-onset (IOPD) form usually comes to medical attention within the first few months of life, either clinically or through newborn screening. The usual presenting features are cardiomyopathy, cardiomegaly, hypotonia, respiratory distress, muscle weakness, feeding difficulties, and failure to thrive. IOPD patients can be further classified by Cross-Reactive Immunological Material (CRIM) status which is an important predictor of clinical response. Patients that produce no GAA protein are referred to as CRIM negative. Therefore, they can develop highly sustained antibody titers for enzyme replacement therapy (ERT). Immunomodulation or immunotherapy is an effective treatment to prevent an immune response to ERT. The main clinical findings include floppy baby appearance, delayed motor milestones, and feeding difficulties. Moderate hepatomegaly may or may not be present. Facial features include macroglossia, hypernasal speech, hearing loss, and myopathic facies. Cardiopulmonary involvement is manifested by increased respiratory rate, use of accessory muscles for respiration, recurrent chest infections, decreased air entry in the left lower zone (due to cardiomegaly), arrhythmias, and evidence of heart failure. Before the development of a treatment, the median age at death in untreated cases was 8.7 months, usually due to cardiorespiratory failure. However, this outcome has drastically changed since enzyme replacement therapy became available, improving with early initiation of treatment.
==== Conceptual history ==== The third season episode "Piper Maru" marked the first occurrence of the black oil. The on-screen appearance of the substance was achieved through visual effects, with the shimmering oil effect being digitally placed over the actors' corneas in post-production. The crew went through various iterations to find the two "right" types of fluids. According to physical effects crewman David Gauthier, they used a mix of oil and acetone, which he believed gave the substance a more globular look. Special effects technician Mat Beck was able to digitally bend the oil effect around the shape of the actors' eyes. The season eight episode, "Vienen", marked the last appearance of the black oil in the series. Molasses and chocolate syrup were used for the visual effects of the black oil. The scene with the black oil coming out of the eyes, ears and mouth was mostly done on a visual effects stage. Due to the uncontrollable nature of the substance, it took nine takes to get the syrup to spill on the right places.
Sources: en.wikipedia.org
=== Molten oxide electrolysis === Molten oxide electrolysis (MOE) uses electrolysis of molten iron oxide to yield metallic iron. It is studied in laboratory-scale experiments and is proposed as a method for industrial iron production that has no direct emissions of carbon dioxide. It uses a liquid iron cathode, an anode formed from an alloy of chromium, aluminium and iron, and the electrolyte is a mixture of molten metal oxides into which iron ore is dissolved. The current keeps the electrolyte molten and reduces the iron oxide. Oxygen gas is produced in addition to liquid iron. The only carbon dioxide emissions come from any fossil fuel-generated electricity used to heat and reduce the metal.
The Special Program of Assisted Reproduction (SPAR) is a program offered to HIV discordant couples (serodiscordant) at the Bedford Research Foundation's clinical laboratory. The program takes advantage of ART (assisted reproduction technology) procedures (including "sperm washing") to assist couples achieve a pregnancy who would otherwise risk transmitting the father's HIV infection to the mother and the child through intercourse. SPAR employs extremely stringent safety standards; samples will only be submitted for "sperm washing" and cryopreservation that have first been screened for HIV virus particles and infected cells by specialized molecular biology tests. Only samples that have been determined to have an undetectable HIV viral burden will be submitted for infertility procedures. Assisted reproductive technologies (ART), such as in vitro fertilization (IVF), treat many disorders of the female, but until recent years, treatment options for male factor infertility were limited, and donor sperm was routinely recommended to achieve a pregnancy. Advances in ART, however, have created new possibilities for men with male factor infertility, including those whose sperm counts have been decreased by cancer treatment and other diseases, and men with incurable, sexually transmissible virus diseases. Infectious diseases transmissible by semen for which there is no cure include:
Grannygate – scandal in March 2000 over the eligibility of Shane Howarth and Brett Sinkinson representing the Wales national team Kamp Staaldraad – controversial training camp for the Springboks (South Africa's national rugby union team) before the 2003 Rugby World Cup "Bloodgate" – a scheme by the English rugby union club Harlequins to fake an injury to wing Tom Williams to allow a blood replacement to be brought on at a critical moment in their 2009 Heineken Cup quarterfinal against Leinster. The scheme, which included deliberately cutting Williams' mouth open after the match in order to cover up the fake injury, ultimately led to Quins head coach Dean Richards being banned from the sport for three years.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.